Stimulating sGC was protective against HF in mice [170], and in humans, stimulating sGC is beneficial in treatment of pulmonary arterial hypertension and HF with reduced Ejection Fraction (HFrEF) [171,172]. The gene discussed is SGCB; the disease is pulmonary arterial hypertension.